Skip to main
ROIV
ROIV logo

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd is positioned positively due to its innovative drug candidate Brepocitinib, which demonstrates a substantial improvement in efficacy with a mean total improvement score (TIS) of 46.5, significantly surpassing expectations and meeting high investor standards. The convenient once-daily (QD) dosing of Brepocitinib offers a clear advantage over the current infusion therapy, IVIg, which has considerable sales of approximately $500 million but involves cumbersome administration for patients. Additionally, the company's diverse pipeline, including promising candidates like VTAMA for psoriasis, further enhances its growth potential in the biopharmaceutical market.

Bears say

Roivant Sciences has faced multiple significant setbacks in its clinical trials, including failures of its drug candidates IMVT, brepocitinib, and mosliciguat, which could undermine investor confidence and stall the company's growth trajectory. These failures reflect a broader trend of lackluster performance in the development pipeline, suggesting potential challenges in bringing successful treatments to market. Consequently, the company's current valuation may not be supported by its future revenue prospects, leading to a negative outlook for its stock.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.